Global Retinal Detachment Disorder Market Size To Exceed USD 3.5 Billion By 2030 | CAGR of 8.3%
18 avr. 2023 07h30 HE
|
SPHERICAL INSIGHTS LLP
New York, United States, April 18, 2023 (GLOBE NEWSWIRE) -- The Global Retinal Detachment Disorder Market Size is To Grow from USD 1.7 Billion in 2021 to USD 3.5 Billion by 2030, at a Compound...
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
12 avr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
11 avr. 2023 07h00 HE
|
ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
13 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
02 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
01 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
26 janv. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Outlook on the Diabetic Retinopathy Global Market to 2027 - Rising Number of Diabetic Patients is Driving Growth
14 nov. 2022 04h13 HE
|
Research and Markets
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type, By Treatment Type, By Regional Outlook and Forecast,...
Global Retinal Surgery Devices Market Analysis Report 2022: A $3.7 Billion Market by 2027 - Consistent Efforts by Healthcare Organizations to Fuel the Market
26 sept. 2022 08h18 HE
|
Research and Markets
Dublin, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy...
Global Nonmydriatic Handheld Fundus Cameras Market to Reach $192.6 Million by 2026
09 sept. 2022 04h13 HE
|
Research and Markets
Dublin, Sept. 09, 2022 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.Global...